结构治疗
GPCR
21.08
-1.11
-5.00%
结构治疗
US · GPCR
#2815 按市值排名
上市于 2023
21.08
-1.11
-5.00%
实时 - 追踪5344个代码 - 心跳于571秒前
· 2026-10-16 19:48
✦ 量化股权信号 计算方式说明
减持
- 最近一期（2026/Q3）披露持股的机构数量减少了4家。
- 机构持股总比例下降了1.8个百分点。
机构持股
- 机构持股比例
- 102.53% -1.77pp
- 机构数量
- 248 -4
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向一致机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流出——两者方向一致。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
Mutual Fund49.12%
Hedge Fund27.66%
VC/PE Fund18.20%
Public Company5.13%
Individual/Insider2.44%
Private Company1.02%
Government Pension Fund0.61%
Sovereign Wealth Fund0.60%
Insurance Company0.10%
主要股东 截至 2026-06-30
FMR
10.90% · 7.78M 股
Deep Track Capital, LP
10.59% · 7.55M 股
Wellington Management Group
10.35% · 7.38M 股
Avoro Capital Advisors LLC
9.19% · 6.56M 股
Janus Henderson Group plc
7.30% · 5.20M 股
BVF Partners L.P.
4.72% · 3.37M 股
Morgan Stanley
3.84% · 2.74M 股
OrbiMed Advisors LLC
3.10% · 2.21M 股
Principal Global Investors, LLC
2.46% · 1.75M 股
American Century Investment Management
2.36% · 1.68M 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪50份申报 · 28次买入 · 22次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| FMR | -- | 10.90% |
| Jun Yoon | Co- Founder, CFO & Secretary | 1.25% |
| Raymond Stevens | Chief Executive Officer | 1.06% |
| Daniel Welch | Independent Chairperson | 0.06% |
| Xichen Lin | Chief Scientific Officer | 0.03% |
| Blai Coll | Vice President of Clinical Development | 0.02% |
| Yingli Ma | Chief Technology Officer | 0.01% |
| Ashley Hall | Chief Development Officer | 0.01% |
| Sharon Tetlow | Independent Director | -- |
| Angus Russell | Director | -- |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-09-20 | Blai Coll | Vice President of Clinical Development | Other Disposition | -4,008 | -- |
| 2026-09-20 | Blai Coll | Vice President of Clinical Development | Other Derivative Acquisition | +4,008 | -- |
| 2026-09-20 | Blai Coll | Vice President of Clinical Development | Open Market Derivative Dispositi | -4,008 | -- |
| 2026-09-17 | Blai Coll | Vice President of Clinical Development | Sale to Issuer | -3,542 | $35.01 |
| 2026-08-31 | Xichen Lin | Chief Scientific Officer | Derivative Exercise and Sale | -17,817 | -- |
| 2026-08-31 | Xichen Lin | Chief Scientific Officer | Derivative Exercise and Sale | -5,939 | $45.86–47.83 |
| 2026-08-17 | Xichen Lin | Chief Scientific Officer | Derivative Exercise and Sale | -11,817 | -- |
| 2026-08-17 | Xichen Lin | Chief Scientific Officer | Derivative Exercise and Sale | -3,939 | $53.13–55.05 |
| 2026-08-05 | John Berrios | -- | Other Acquisition | +140,766 | -- |
| 2026-08-05 | John Berrios | -- | Other Derivative Acquisition | +174,612 | $17.54 |
| 2026-08-03 | Xichen Lin | Chief Scientific Officer | Derivative Exercise and Sale | -11,817 | -- |
| 2026-08-03 | Xichen Lin | Chief Scientific Officer | Derivative Exercise and Sale | -3,939 | $49.29–50.03 |
| 2026-07-13 | Xichen Lin | Chief Scientific Officer | Other Acquisition | +7,878 | -- |
| 2026-07-13 | Xichen Lin | Chief Scientific Officer | Open Market Disposition | -7,878 | $50.80–51.71 |
| 2026-07-13 | Xichen Lin | Chief Scientific Officer | Derivative Exercise and Sale | -23,634 | -- |
| 2026-07-13 | Xichen Lin | Chief Scientific Officer | Other Derivative Acquisition | +7,878 | -- |
| 2026-07-13 | Xichen Lin | Chief Scientific Officer | Open Market Derivative Dispositi | -7,878 | -- |
| 2026-06-24 | Xichen Lin | Chief Scientific Officer | Other Acquisition | +7,878 | -- |
| 2026-06-24 | Xichen Lin | Chief Scientific Officer | Open Market Disposition | -7,878 | $49.08 |
| 2026-06-24 | Xichen Lin | Chief Scientific Officer | Derivative Exercise and Sale | -23,634 | -- |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 19:48:34 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
结构治疗 讨论区 0 条评论